Sugi Predict

Sugi Predict / Compounds / SCHEMBL2406847

SCHEMBL2406847

SCHEMBL2406847

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCc3ccnc(NC(=O)CN4CCOCC4)c3)c3ccccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 19/20 1.00
▸ HCK P08631 15/20 1.00
▸ MAPK12 P53778 15/20 1.00
▸ SRC P12931 3/20 0.78
▸ TNF P01375 3/20 0.72
▸ MAPK13 O15264 2/20 0.72
▸ MAPK11 Q15759 2/20 0.72
▸ CIT O14578 1/20 0.72
▸ MUSK O15146 1/20 0.72
▸ MAP3K7 O43318 1/20 0.72
▸ RIPK2 O43353 1/20 0.72
▸ STK10 O94804 1/20 0.72
▸ MAP4K4 O95819 1/20 0.72
▸ CHEK2 O96017 1/20 0.72
▸ ABL1 P00519 1/20 0.72
▸ EGFR P00533 1/20 0.72
▸ RAF1 P04049 1/20 0.72
▸ NTRK1 P04629 1/20 0.72
▸ HSPB1 P04792 1/20 0.72
▸ PRKCB P05771 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406761 0.94 MAPK14 (0.89) MAPK14HCKMAPK12SRCTNF
SCHEMBL2406468 0.93 MAPK14 (0.86) MAPK14HCKMAPK12SRCGSK3B
SCHEMBL13563488 0.92 MAPK14 (0.84) MAPK14HCKMAPK12SRCTNF
SCHEMBL12540620 0.91 MAPK14 (0.84) MAPK14HCKMAPK12SRCTNF
SCHEMBL12540236 0.91 MAPK14 (0.84) MAPK14HCKMAPK12SRCTNF
SCHEMBL12540820 0.91 MAPK14 (0.83) MAPK14HCKMAPK12SRCTNF
SCHEMBL2407124 0.90 MAPK14 (0.82) MAPK14HCKMAPK12SRCTNF
SCHEMBL17965526 0.90 MAPK14 (0.82) MAPK14HCKMAPK12SRCTNF
SCHEMBL12540807 0.90 MAPK14 (0.82) MAPK14HCKMAPK12SRCTNF
SCHEMBL13563468 0.89 MAPK14 (0.86) MAPK14HCKMAPK12SRCTNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370428-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2016-08-10 — — EP claimed
US-20140114064-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2014-04-24 — — US claimed
EP-2350049-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2014-02-26 — — EP claimed
US-8299073-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2012-10-30 — — US claimed
US-8293748-B2 p38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2012-10-23 — — US claimed
US-20110294812-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-12-01 — — US claimed
US-20110212962-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-09-01 — — US claimed
EP-2509595-B1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION RESPIVERT LTD (GB) 2018-04-11 — — EP disclosed
EP-2509595-B1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION RESPIVERT LTD (GB) 2018-04-11 — — EP disclosed
US-20180000830-A1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION RESPIVERT LIMITED (GB) 2018-01-04 — — US disclosed
US-20180000830-A1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION RESPIVERT LIMITED (GB) 2018-01-04 — — US disclosed
EP-2370428-B1 P38 MAP KINASE INHIBITORS RESPIVERT LTD (GB) 2016-08-10 — — EP disclosed
US-20160045512-A1 Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection RESPIVERT LIMITED (GB) 2016-02-18 — — US disclosed
US-8293748-B2 p38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2012-10-23 — — US disclosed
US-20120244120-A1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION RESPIVERT LTD. (GB) 2012-09-27 — — US disclosed
US-20120244120-A1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION RESPIVERT LTD. (GB) 2012-09-27 — — US disclosed
US-20110294812-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-12-01 — — US disclosed
US-20110294812-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-12-01 — — US disclosed
US-20110212962-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-09-01 — — US disclosed
US-20110212962-A1 P38 MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2011-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180000830-A1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION HCK, CDK9, PHKG1 MAPK14 257/4885HCK 1/4885MAPK12 621/4885
US-20120244120-A1 INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION HCK, CDK9, TTK MAPK14 418/4885HCK 1/4885MAPK12 634/4885
US-20110294812-A1 P38 MAP KINASE INHIBITORS MAPK1, MAP3K1, MAPK3 MAPK14 10/4885HCK 348/4885MAPK12 13/4885
US-20110212962-A1 P38 MAP KINASE INHIBITORS MAPK1, MAPK3, MAPK6 MAPK14 33/4885HCK 2830/4885MAPK12 31/4885
US-20140114064-A1 P38 MAP KINASE INHIBITORS MAPK1, MAPK3, MAPK6 MAPK14 33/4885HCK 2830/4885MAPK12 31/4885
US-20160045512-A1 Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza Infection HCK, CDK9, TTK MAPK14 418/4885HCK 1/4885MAPK12 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.